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Abstract 
Background: Growing evidences suggest that patients with irritable bowel syndrome (IBS) 
have increased intestinal permeability. In addition, mucosal soluble mediators are involved in 
the pathophysiology of pain in IBS. We aimed to investigate: (1) paracellular permeability in 
colonic biopsies of IBS patient (2) the ability of soluble factors from colonic biopsies to 
reproduce in vitro these alterations. Methods: Paracellular permeability was measured in 
colonic biopsies of IBS patients and healthy subjects mounted in Ussing chambers. Cleared 
supernatant (SUP) of culture from colonic biopsies was collected and applied to Caco-2 cells 
for 48h. Paracellular permeability and transepithelial resistance (TER) were evaluated. mRNA 
expression of the tight junction (TJ) proteins, zonula occludens (ZO)-1 and occludin, was 
assessed in colonic biopsies. Abdominal pain was assessed using a validated questionnaire. 
Results: Permeability of colonic biopsies was significantly higher in IBS compared to healthy 
subject. These changes were associated with significantly lower expression of ZO-1 mRNA in 
biopsies of IBS as compared to healthy subjects. Compared to healthy subjects, SUP of IBS 
markedly reduced TER and significantly increased permeability in Caco-2 cells. SUP of IBS 
patients induced a significant decrease of ZO-1 mRNA in Caco-2 as compared to healthy 
subjects. SUP-induced increased paracellular permeability correlated with the severity of 
abdominal pain. Conclusions: Our study shows that colonic soluble mediators are able to 
reproduce functional (permeability) and molecular (ZO-1 mRNA expression) alterations 
observed in IBS patients. These findings might pave the way both to identify novel 
biomarkers as well as new therapeutic targets in IBS.  
 
 
Introduction 
The irritable bowel syndrome (IBS) is characterized by abdominal discomfort or pain 
and changes in bowel habit in the absence of an identifiable disease process (1). Currently, the 
symptoms of IBS involve interactions among central nervous system component, peripheral 
dysfunction and low-grade inflammation and/or previous intestinal infection (2). In addition 
to this classical view, emerging evidences suggest that other factors, including altered 
intestinal permeability, can contribute to IBS and related symptoms (3). Intestinal 
permeability exerts a key role in the interplay between host and external environment. The 
paracellular permeability of the intestinal epithelial barrier (IEB) is regulated by a complex 
protein system that constitute tight junctions (TJs). TJs are composed of the transmembrane 
proteins occludin and claudins that interact with the zonula occludens (ZO) proteins which 
bind to the actin cytoskeleton to control paracellular permeability (4, 5).  
Recent studies have shown that an IBS subgroup present with an increased intestinal 
permeability (6, 7, 8). However, conflicting results between post-infectious and unselected 
IBS patients have been reported (6, 7). In one recent study, small intestinal permeability was 
increased in unselected diarrhoea-predominant and post-infectious IBS as compared to 
constipation-predominant IBS (8). Furthermore, a recent study has demonstrated that colonic 
soluble factors contained in faecal homogenates of IBS patients with predominance of 
diarrhoea increased paracellular permeability in mice (9). However, whether paracellular 
permeability is altered in the colon of IBS patients remains unknown.  
Soluble mediators released by the intestinal mucosa of IBS patients could also play a 
role in painful symptoms generation. Indeed, recent investigations have shown that soluble 
factors released from biopsies or from the colonic lumen of IBS patients could induced in vivo 
visceral hyperalgesia (9, 10, 11). These effects were shown to be mediated via the release of 
various mediators such as histamine or tryptase (9, 10, 11). Furthermore, the effect of soluble 
factors upon visceral hypersensitivity could be the result of an increase in paracellular 
permeability induced by these factors (9). However, whether soluble factors can directly 
modify paracellular permeability of the IEB remains currently unknown.  
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Therefore, we aimed to investigate: (1) paracellular permeability in colonic biopsies of 
IBS patients; (2) the ability of soluble factors from colonic biopsies to reproduce in vitro 
alterations of IEB integrity.  
 
Material and Methods 
Subjects  
Consecutive patients who met the Rome II criteria for IBS (1) were seen in the 
Department of Internal Medicine and Gastroenterology of the University of Bologna and the 
Department of Gastroenterology of the Centre Hospitalier Universitaire de Nice. Healthy 
subjects were recruited by public advertisement after thorough exclusion of gastrointestinal 
symptoms. None were taking anti-inflammatory drugs (including mast cell stabilizers, 
histamine antagonists, anticholinergics, anti-diarrhoea medication, probiotics, 
immunosuppressants, and steroids) or had any organic syndrome, including food allergy, 
coeliac disease, atopy and severe clinical depression or anxiety. Smoking habits of healthy 
subject or IBS patients were not recorded. They all gave written informed consent, and the 
study was approved by the two local Ethical Committees (Bologna and Nice) and conducted 
in accordance with the Declaration of Helsinki.  
 Patients were asked to score frequency and severity of symptoms over the last 2 weeks 
before interview according to previously validated questionnaires (12). The severity of 
abdominal pain/discomfort was scored 0-4 according to its impact on patients’ daily activities: 
0, absent; 1, mild (not influencing activities); 2, relevant (diverting from, but not urging 
modification of activities); 3, severe (influencing activities markedly enough to urge 
modifications); 4, extremely severe (precluding daily activities). The frequency of abdominal 
pain/discomfort was graded 0-4 according to the following scale: 0, absent; 1, up to 1 
day/week; 2, 2 or 3 days/week; 3, 4-6 days per week; 4, daily. All clinical interviews were 
done within two weeks before the colonoscopy.  
 
Collection and assay of mucosal mediators 
 A left colonoscopy without sedation was performed in participants after cleansing of 
distal colon with two 500-mL water enemas performed before the procedure. For all 
participants, 2 mucosal biopsies were obtained for routine H&E histology to exclude the 
presence of microscopic colitis. One biopsy was placed in Eppendorf RNAse free tubes, snap 
frozen in liquid nitrogen, and maintained at –70°C. Upon removal, 2 other biopsies were 
rapidly immersed in hard plastic tubes containing 1 ml of Hank’s buffer saline solution 
(HBSS, Invitrogen, Cergy-Pontoise, France), continuously oxygenated (95% O2/5% CO2) at 
37°C. After 20 min incubation, the solution was removed and centrifugated at 200g for 10 
min before being filtered with centrifuge tube filters (0.22µm, SPIN-X, Corning, NY, USA) 
to remove bacterial components. Aliquots of 200 μl of supernatant (SUP) were stored at –
70°C until assays. Biopsies were blotted and weighted after collecting the SUP. In 13 IBS 
patients and 5 healthy subjects, 4 biopsies were taken for the purpose of paracellular 
permeability as described below. None of these subjects were smokers. 
 
Paracellular permeability of colonic biopsies in Ussing chambers 
 Paracellular permeability in colonic biopsies was measured as previously described 
(13). Four standard biopsies were mounted in adapted Ussing chambers (Transcellab, TBC, 
Paris, France) exposing a surface of 0.0314 cm2. Tissues were bathed on each side with 3 mL 
of Ham’s Nutrient Mixture (HAM’s F12, Invitrogen, France). The medium was continuously 
oxygenated and maintained at 37°C by a gas flow (95% O2,/5% CO2). After a 15 min baseline 
period, 150 μl of apical medium was replaced by 150 μl of fluorescein–5.6 sulfonic acid (10 
mg/mL) (400 D, Invitrogen, France). The fluorescence level of basolateral aliquots of 150 μl 
was measured at 30 min interval during 180 min using a fluorimeter (Tecan Infinite F500, 
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Tecan SA, France). Fluorescence values were converted in concentrations of fluorescein 
(ng/mL) using a standard curve. Values of permeability at 180 min were the mean of 4 
biopsies with individual coefficient of variability less than 5.2%.  
 
Caco-2 cells  
 Experiments were performed with the human intestinal epithelial cell lines Caco-2 
(EATCC, Port Down, UK). Cells were seeded onto porous filters (12-well Transwell Clear, 
0.40 μm porosity, 1.1 cm of diameter, Corning, ATGC, Marne la Vallée, France), at a density 
of 200,000 cells/filter and cultured in DMEM (4.5 g/l glucose; Invitrogen) supplemented with 
10% heat-inactivated FCS (Abcys, Paris, France), 2 mM glutamine (Invitrogen) and 50 IU/ml 
penicillin, and 50 µg/ml streptomycin (Invitrogen). After 14 days of culture, Caco-2 cells 
formed differentiated and polarised monolayer. The culture medium was changed every 2 
days.  
 
Experimental protocol 
Caco-2 cell monolayers were incubated for 48 hours with SUP of healthy subjects or 
IBS patients. The SUP was added onto the apical and basolateral side of Caco-2 monolayers. 
The volume of SUP was normalized to the weight of biopsies (150 μl for 5 mg) in order to 
add similar concentrations of soluble mediators (e.g. SUP was diluted once the biopsy weight 
was known). Control solutions were also performed by adding similar volumes of HBSS than 
SUP. 
 
Resistances and paracellular permeability of Caco-2 cells 
 
 Caco-2 monolayer transepithelial resistances (TER) were measured with an epithelial 
volt-ohmmeter (WPI, Stevenage, UK) before and after 24 and 48 hours incubation with SUP. 
Results (Ω) are presented as differences compared to basal values. 
 Paracellular permeability studies were performed using the flux of Dextran-FITC 
through Caco-2 monolayer as previously described (14). At the end of the 48 hours incubation 
period, 150 μL of FITC-conjugated dextran (4kDa, 10 mg/mL; Sigma, Saint Quentin 
Fallavier, France) were added to the apical compartment. Basolateral aliquots were taken after 
8 hours and the fluorescence level was measured in a 96-wells fluorescent plate reader using a 
fluorimeter at 496 nm (PerkinElmer, Courtaboeuf, France). Values were converted in 
concentrations of FITC dextran (ng/mL) using a standard curve. 
 
ZO-1 and occludin mRNA expression by real-time quantitative polymerase chain reaction 
(RT-qPCR) 
Total RNA was extracted from cells using RLT (Qiagen, Courtaboeuf, France) 
according to the manufacturer’s instructions. Total RNA (5µg), pd(N)6 random hexamers 
(1µl, 265ng/µl) (GE Healthcare, Orsay, France) dNTPs (1µl, 10mM) (Invitrogen), first strand 
buffer 5X ( 5µl) (Invitrogen), DDT (1µl, 0,1M) (Invitrogen), and RNasin (0,5µl, 40 U/µl) 
(Promega, Charbonnieres, France) were used to synthesize single-stranded cDNA using the 
Superscript II Reverse Transcriptase (Invitrogen; 0,5µl, 200 U/µl) in a total volume of 25μl. 
Incubation was performed at 42°C for 60 min. Amplification conditions for S6 (house 
keeping gene), ZO-1 and occludin were optimized for the RotorGene 2000 instrument 
(Ozyme, Saint Quentin en Yvelines, France). PCRs were performed with 2 μl of cDNA, 0.1μl 
of a solution of SYBR Green I diluted at 1 :100 (Sigma), 1 µl (10 µM) of each primer, 1µl (10 
mM) dNTPs, and 0,4µl of Titanium Taq DNA polymerase kit (Ozyme). Cycling conditions 
were as follows: 5 min at 95°C; amplification for 40 cycles, with denaturation for 5 s at 95°C, 
annealing for 15 s (66°C for S6 and ZO-1), (68°C for Occludin) and extension for 15 s at 
72°C. The following primers were used: 
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 S6 forward 5’- CCAAGCTTATTCAGCGTCTTGTTACTCC-3’ ; S6 reverse 5’-
CCCTCGAGTCCTTCATTCTCTTGGC -3’ (PCR product 130 pb) ; 
ZO-1 forward 5’- GAATGATGGTTGGTATGGTGCG -3’ ; ZO-1 reverse 5’- 
TCAGAAGTGTGTCTACTGTCCG -3’ (PCR product 191 pb); 
Occludin forward 5’- ATGAGACAGACTACACAACTGG -3’; 
Occludin reverse 5’- TTGTATTCATCAGCAGCAGC -3’ (PCR product 252 pb).  
All PCR products were sequenced to validate the specificity of the amplification. 
An external standard curve was generated with serial dilutions of control cDNA , by 
plotting the relative amounts of these dilutions against the corresponding Ct (threshold cycle) 
values. The amount of ZO-1, occludin and S6 was calculated from these standard curves 
using the RotorGene software (Ozyme). Samples were tested in triplicate and the average 
values were used for quantification using the 2-ΔΔCT method as previously described (15).  
 
Pharmacological tools 
Histamine (Sigma) was added to the apical and basolateral compartment of Caco-2 
monolayer at a final concentration of 10μM. Chlorpheniramine (histamine-1 receptor 
antagonist, Sigma), Cimetidine (histamine-2 receptor antagonist, Sigma) and Thioperamide 
(histamine-3/4 receptor antagonist, Sigma) were used at the following final concentrations 
dissolved in sterile water, 10-5 M, 10-4 M and 10-6 M, respectively. Differentiated Caco-2 
monolayers were first treated during 30 min with a cocktail of histamine receptor antagonists, 
prior to the addition of SUP of both healthy subjects and IBS patients for 48 hours. 
 
Statistical analysis 
Data were expressed as mean±SD or median and interquartile ranges and were 
compared using non-parametric Mann Whitney U test or ANOVA with post-tests when 
appropriate. Relationships between permeability and TER, abdominal pain severity and TJs 
expression were assessed by linear regression. A p value < 0.05 was considered significant. 
 
 
Results  
 Fifty one IBS patients and fourteen healthy subjects were included in the study. The 
clinical characteristics of IBS patients are described in Table 1 according to IBS subtypes.  
 
Paracellular permeability of colonic biopsies 
 Paracellular permeability of colonic biopsies at 180 min of culture was significantly  
higher in IBS patients (107±30 ng/mL, n=12) compared with healthy subjects (66±5 ng/mL, 
n=5, p=0.01). There was no difference among IBS subtypes (Figure 1). In IBS patients, a 
statistical trend was observed between the severity of abdominal symptoms and paracellular 
permeability of colonic biopsies (r=0.55, p=0.06). However, no correlation was found 
between the frequency of abdominal pain and paracellular permeability. 
 
ZO-1 and occludin expression in colonic biopsies 
 ZO-1 mRNA expression was significantly lower in biopsies of IBS patients compared 
to healthy subjects (1.2±2.0 vs 14.0±28.8, p=0.04) (Figure 2A). Occludin mRNA expression 
was similar between IBS patients and healthy subjects (17.5±36 vs 14±25, p=0.7) (Figure 
2B). There was an inverse correlation between the expression of ZO-1 mRNA expression in 
colonic biopsies and the paracellular permeability induced in Caco-2 by SUP of the 
corresponding IBS patient (r=-0.56, p=0.01).  
 
Effect of SUP on TER and paracellular permeability of Caco-2 cells 
 on 20 October 2008 gut.bmj.comDownloaded from 
  
6
6
 After forty-eight hours, SUP of IBS induced a significant fall in TER of Caco-2 
monolayer (-100±66 Ω, n=39) compared to that of healthy subjects (–9±32 Ω, n=14 
p<0.0001) and control solutions (–13±37, n=12 p<0.0001) (Figure 3). Interestingly, changes 
in TER were similar among IBS subtypes at any time-points (data not shown). SUP of IBS 
patients applied to Caco-2 cells induced a significant increase of paracellular permeability 
(1218±265 ng/mL, n=39) compared to SUP of healthy subjects (989±117 ng/mL, n=14, 
p=0.001) and control solutions (1042±121 ng/mL, n=12, p=0.01) (Figure 4). In IBS patients, 
there was a significant inverse correlation between paracellular permeability and changes in 
TER (r=-0.63, p<0.0001). Paracellular permeability was similar among IBS subtypes (Figure 
4). 
 In IBS patients, the severity of abdominal pain was significantly associated with 
paracellular permeability (Figure 5). This correlation was more stringent in IBS patients with 
predominance of diarrhoea (r=0.65, p=0.01) than in patients with predominance of 
constipation (r=0.56, p=0.02). However, no correlation was found in IBS patients with 
alternating symptoms. In addition, the frequency of abdominal pain was not correlated with 
paracellular permeability in IBS patients. Paracellular permeability and the severity of 
abdominal pain were not associated with age or gender of patients. 
 
Effect of SUP on ZO-1 and occludin expression on Caco-2 cells 
 ZO-1 mRNA expression was significantly lower in Caco-2 incubated with SUP of IBS 
patients than with SUP of healthy subjects (1.6±2.4 vs 10.3±16.0, p=0.01) (Figure 6A). In 
contrast, the expression of occludin mRNA was similar between IBS patients and healthy 
subjects (Figure 6B). There was no difference between IBS subtypes. A trend to an inverse 
correlation was observed between the expression of ZO-1 mRNA in Caco-2 cells and 
paracellular permeability in IBS patients (r=-0.35, p=0.09). In addition, no change was 
observed in the pericellular distribution of ZO-1 in Caco-2 monolayers incubated with SUP of 
IBS or healthy subjects (data not shown).  
 
Effect of histamine and receptor antagonists on TER and paracellular permeability of Caco-2 
cells 
 Compared to control solution, changes in TER were not modified after addition of 
histamine (10 μM) to Caco-2 cells for 16 hours as compared to control (57.6±23.7 vs. 
40.0±52.6 Ω, n=6, p=0.4). In addition, histamine did not altered significantly paracellular 
permeability of Caco-2 cells compared to control solution (1113±221 vs. 1337±376 ng/mL, 
p=0.3 respectively). Changes in TER and paracellular permeability of Caco-2 monolayers 
incubated with SUP of IBS patients (n=6) or healthy subjects (n=4) were not significantly 
modified by a pre-treatment with a cocktail of histamine receptor antagonists (data not 
shown). 
 
 
Discussion 
The current study showed that paracellular permeability of colonic biopsies of IBS 
patients is increased irrespective of IBS subtypes. Moreover soluble mediators released from 
colonic biopsies of IBS patients induced a significant increase in the paracellular permeability 
of Caco-2 cell monolayers as compared to healthy subjects. Of interest, the magnitude of 
increase in permeability was positively correlated with abdominal pain severity of IBS 
patients. In addition, SUP of IBS patients induced a concomitant decrease in ZO-1 but not 
occludin mRNA expression in Caco-2 as compared to healthy subjects. A similar significant 
decrease in ZO-1, but not occludin, mRNA expression was also observed in colonic biopsies 
of IBS patients as compared to healthy subjects. In our experiments, the role of histamine as a 
candidate mediator is unlikely.  
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 A growing body of evidence suggests that disturbances of IEB functions, in particular 
enhanced gut permeability, may play a contributory role in the sequence leading to gut 
dysfunction and generation IBS symptoms. Indeed, using the lactulose/mannitol test, elevated 
intestinal permeability has been documented in 12 to 50% of IBS patients, depending on the 
infective nature of IBS, inclusions of patients with adverse reaction to food or various IBS 
criteria (7, 16-19). More recently, Dunlop et al. (8) found highest small bowel permeability in 
non post-infectious compared to post-infectious IBS or healthy subjects, and in IBS with 
predominance of diarrhoea compared to IBS with predominance of constipation and healthy 
subjects. Our study extents previous findings of increased permeability detected in the small 
intestine of IBS patients to the colon by showing that 1) paracellular permeability is also 
increased in the human colon of IBS patients and 2) in contrast to the small intestine, this 
increase (observed in colonic biopsies and also induced by soluble factors from biopsies) is 
independent of IBS subtypes. Interestingly, this latter finding is in contrast with the data of 
Gecse et al. (9) who showed that only SUP of IBS patients with predominance of diarrhea 
bowel habit could increase paracellular permeability. These differences could result from the 
fact that alterations of paracellular permeability described by Gecse et al. (9) were observed 
following acute administration of SUP (1h), whereas we performed a more prolonged 
administration of SUP (48h). This point also further justified the use of transformed intestinal 
epithelial cell lines as they can survive for long time in contrast to mucosal biopsies which 
showed functional alterations as early as 4 to 6 hours (20). Another important finding was that 
changes of paracellular permeability was related to a direct effect of SUP upon intestinal 
epithelial cells. Indeed, integrated studies performed in vivo/ex vivo cannot excluded that 
effects of SUP upon permeability were mediated via the activation of other cells from the 
mucosa such as nerves or immune cells which are known to control IEB functions (for 
review, see 21). This is of particular interest in attempt to identify new biomarkers for 
therapeutic intervention in IBS. Indeed, alterations of ZO-1 expression that we observed in 
colonic biopsies or that were induced by SUP in caco-2 cells could be a direct marker of IEB 
dysfunction in IBS. 
The causes underlying pain in IBS are still poorly understood. Enhanced permeability 
has been suggested as an etiologic factor in several inflammatory conditions associated with 
pain, including Crohn’s disease (22), coeliac disease (23) and acute gastroenteritis (24). A 
cause-effect relationship between mucosal barrier alterations and visceral hypersensitivity has 
been described in a recent animal study in which the chemical blockade of enhanced colonic 
paracellular permeability induced by stress was accompanied by a decrease sensitivity to 
colonic distension (25). Our present findings suggest that the correlation between paracellular 
permeability and pain scores of IBS patients could be related to the effect of soluble 
mediators released from biopsy specimens. Interestingly, similar findings were obtained using 
colonic biopsies of IBS patients. It has been recently demonstrated that IBS patients had a 
marked increase in colonic mucosal area occupied by mast cells with increased release of 
histamine and tryptase compared to healthy subjects (12). Moreover, the severity of 
abdominal pain of IBS patients was directly related to the proximity between activated mast 
cells and mucosal nerves (12).  
Our study also suggests a molecular basis for the SUP-induced increase in permeability, 
involving the TJs complex. Indeed, SUP of IBS patients, but not of healthy subjects, induced 
a significant reduction in ZO-1 mRNA expression in Caco-2 cells. Interestingly, a significant 
decrease of ZO-1 mRNA expression was also observed in colonic biopsies of IBS patients but 
not of healthy subjects. Finally, there was a trend of inverse correlation between ZO-1 mRNA 
expression in Caco-2 monolayers and paracellular permeability and a strong significant 
inverse correlation between these parameters in colonic biopsies of IBS patients. All these 
findings indicate that mediators released from colonic biopsies of IBS patients could increase 
permeability by altering the expression of TJ proteins, in particular ZO-1. This observation is 
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in agreement with the role of ZO-1 in the control of paracellular permeability. Indeed, various 
factors known to reduce permeability have been shown to increase ZO-1 expression both at 
the mRNA and protein level (13,14). Similarly, in diseases with increased permeability a 
reduction of ZO-1 expression and mRNA has also been observed (26). Whether the reduction 
of mRNA expression is associated with decreases of ZO-1 proteins remains unknown. 
Measurements of ZO-1 mRNA expression in biopsies of IBS patients could be used as a 
marker of the alteration in the IEB permeability. Indeed, we found an inverse correlation 
between ZO-1 mRNA expression in biopsies and permeability changes of Caco-2 induced by 
SUP coming from same patients. 
Mediators released by biopsies responsible for the effects on IEB still remain to be 
identified. Previous studies (10, 11) have shown that candidates such as protease and 
histamine are involved in the effects of SUP of IBS upon the neuronal excitability. In our 
study, we choose first to explore the role of histamine because of its well-known involvement 
in the secretory response of the IEB in diseases such as allergy and inflammatory bowel 
diseases (27, 28). Histamine also induces a secretory response in a human intestinal epithelial 
cell line and in mouse distal colon (29). However, the in vitro effects of histamine and/or 
various types of histamine receptor antagonists on paracellular permeability have lead to 
controversial findings, depending on the type of cell line and designs of studies (30-33). Our 
data suggest that histamine has no effect upon the regulation of the IEB paracellular 
permeability in vitro. Taken together, these data suggest that histamine could be involved in 
the increased viscerosensitivity in IBS, but not in the increased paracellular permeability. 
Finally, a recent study has shown that SUP of IBS increases paracellular permeability via 
activation of PAR-2 receptors (9). Whether such pathways are involved in our observations 
are the focus of ongoing studies. 
In conclusion, these data suggest that alterations of the integrity of IEB are present in 
colonic biopsies of IBS patients. Soluble mediators from colonic biopsies are involved in 
these alterations by affecting TJs expression. These findings suggest that agents aimed at 
reinforcing IEB function could be a novel therapeutical target in IBS. 
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Table 1: Clinical characteristics of IBS patients. 
IBS subtype IBS-C IBS-D IBS-A P value 
Sex (M/F) 2/17 7/10 2/13 - 
Age (y) 43.6 [22-65] 45.1 [19-71] 47.2 [20-78] 0.8 
Abdominal pain severity  
(mean score and SD) 
2.5 ±0.8 2.6±0.9 2.1±0.8 0.3 
Abdominal pain frequency 
(mean score and SD) 
2.5±0.6 2.6±0.8 2.7 ±1.0 0.5 
NOTE: IBS-C, predominant constipation; IBS-D, predominant diarrhoea; IBS-A, constipation 
alternating with diarrhoea. Values in brackets are minimum and maximum.
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Figure Legends  
 
Figure 1 : Paracellular permeability to FITC-sulfonic acid (expressed in ng/mL) in colonic 
biopsies of IBS patients (n=12) and healthy subjects (n=5). IBS patients are also shown 
according to IBS subtypes. IBS-C; predominance of constipation (n=3). IBS-D; predominance 
of diarrhoea (n=4), IBS-A; alternating symptoms (n=5).* p<0.05 vs. healthy subjects. Dotted 
lines are mean values. 
 
Figure 2: Tight junction proteins (ZO-1 and occludin) mRNA expression in colonic biopsies 
of IBS patients (n=21) and healthy controls (n=12). Results are medians and interquartile 
ranges. * p=0.03 vs. healthy subjects. 
 
Figure 3: Effect of 48 hours incubation of Caco-2 cells with supernatant of patients with IBS 
(n=39) and healthy controls (n=14) on the variations of transepithelial resistance (∆ TER, Ω) 
at day 1 and day 2. a p=0.01, b  p<0.0001 vs. healthy subjects. Results are means ± SD. 
 
Figure 4:  Effect of 48 hours incubation of Caco-2 cells with supernatant of patients with IBS 
(n=39) and healthy controls (n=14) on paracellular permeability to FITC-Dextran of Caco-2 
monolayer (expressed in ng/mL). IBS patients are also shown according to IBS subtypes. 
IBS-C; predominance of constipation (n=15). IBS-D; predominance of diarrhoea (n=14), IBS-
A; alternating symptoms (n=10).* p<0.05, ** p<0.01 vs. healthy subjects. Dotted lines are 
mean values. 
 
Figure 5: Paracellular permeability of Caco-2 cells as a function of the severity of abdominal 
pain in 39 patients with IBS. * p=0.006.  
 
Figure 6: Effect of 48 hours incubation of Caco-2 cells with supernatant of patients with IBS 
(n=23) and healthy controls (n=6) on ZO-1 and occludin mRNA expression. Results are 
medians and interquartile ranges. * p=0.04 vs. healthy subjects.  
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